Financials

News Ideas Discussions Technicals Forecast Seasonals

Total liabilities & shareholders' equities of Avalo Therapeutics, Inc.

Annual data

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

‪0.00‬

‪‪21.00 M‬‬

‪‪42.00 M‬‬

‪‪63.00 M‬‬

‪‪84.00 M‬‬

Period

Value

Change

Change %

2023

‪‪20.99 M‬‬

‪‪−12.37 M‬‬

‪−37.08‬%

2022

‪‪33.37 M‬‬

‪‪−46.85 M‬‬

‪−58.40‬%

2021

‪‪80.21 M‬‬

+‪‪36.46 M‬‬

+‪83.32‬%

2020

‪‪43.76 M‬‬

+‪‪7.65 M‬‬

+‪21.18‬%

2019

‪‪36.11 M‬‬

‪‪−34.14 M‬‬

‪−48.60‬%

2018

2017

2016

2015

2014

Quarterly data

Q4 '16

Q1 '17

Q2 '17

Q3 '17

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

‪0.00‬

‪‪35.00 M‬‬

‪‪70.00 M‬‬

‪‪105.00 M‬‬

‪‪140.00 M‬‬

Period

Value

Change

Change %

Q3 '24

‪‪98.45 M‬‬

‪‪−9.85 M‬‬

‪−9.10‬%

Q2 '24

‪‪108.31 M‬‬

‪‪−15.42 M‬‬

‪−12.46‬%

Q1 '24

‪‪123.73 M‬‬

+‪‪102.73 M‬‬

+‪489.38‬%

Q4 '23

‪‪20.99 M‬‬

‪‪−8.28 M‬‬

‪−28.28‬%

Q3 '23

‪‪29.27 M‬‬

+‪‪5.04 M‬‬

+‪20.78‬%

Q2 '23

‪‪24.23 M‬‬

‪‪−12.00 M‬‬

‪−33.12‬%

Q1 '23

‪‪36.23 M‬‬

+‪‪2.87 M‬‬

+‪8.60‬%

Q4 '22

‪‪33.37 M‬‬

‪‪−3.18 M‬‬

‪−8.70‬%

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q3 '19

Q2 '19

Q1 '19

Q4 '18

Q3 '18

Q2 '18

Q1 '18

Q4 '17

Q3 '17

Q2 '17

Q1 '17

Q4 '16